{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:53:40Z","timestamp":1789872820204,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T00:00:00Z","timestamp":1438905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T00:00:00Z","timestamp":1438905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Approximately 30\u00a0% of juvenile idiopathic arthritis (JIA) patients fail to respond to anti-TNF treatment. When clinical remission is induced, some patients relapse after treatment has been stopped. We tested the predictive value of MRP8\/14 serum levels to identify responders to treatment and relapse after discontinuation of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples from 88 non-systemic JIA patients who started and 26 patients who discontinued TNF-blockers were analyzed. MRP8\/14 serum levels were measured by in-house MRP8\/14 ELISA and by B\u00fchlmann Calprotectin ELISA at start of anti-TNF treatment, within 6\u00a0months after start and at discontinuation of etanercept in clinical remission. Patients were categorized into responders (ACRpedi\u2009\u2265\u200950 and\/or inactive disease) and non-responders (ACRpedi\u2009&lt;\u200950) within six months after start, response was evaluated by change in JADAS-10. Disease activity was assessed within six months after discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline MRP8\/14 levels were higher in responders (median MRP8\/14 of 1466\u00a0ng\/ml (IQR 1045\u20133170)) compared to non-responders (median MRP8\/14 of 812 (IQR 570\u20131178), p\u2009&lt;\u20090.001). Levels decreased after start of treatment only in responders (p\u2009&lt;\u20090.001). Change in JADAS-10 was correlated with baseline MRP8\/14 levels (Spearman\u2019s rho 0.361, p\u2009=\u20090.001). Patients who flared within 6\u00a0months after treatment discontinuation had higher MRP8\/14 levels (p\u2009=\u20090.031, median 1025\u00a0ng\/ml (IQR 588\u20131288)) compared to patients with stable remission (505\u00a0ng\/ml (IQR 346\u2013778)). Results were confirmed by B\u00fchlmann ELISA with high reproducibility but different overall levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High levels of baseline MRP8\/14 are associated with good response to anti-TNF treatment, whereas elevated MRP8\/14 levels at discontinuation of etanercept are associated with higher chance to flare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-015-0723-1","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T06:56:51Z","timestamp":1438757811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"17","author":[{"given":"Janneke","family":"Anink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette W. A.","family":"Van Suijlekom-Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke H.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H. M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion A. J.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert M.","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther P. A. H.","family":"Hoppenreijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faekah","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Holzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,7]]},"reference":[{"key":"723_CR1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638\u201344.","journal-title":"Ann Rheum Dis"},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Pediatric Rheumatology Collaborative Study G: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496\u2013504.","journal-title":"Arthritis Rheum"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635\u201341.","journal-title":"Ann Rheum Dis"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340\u20137.","journal-title":"JAMA"},{"key":"723_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3899\/jrheum.120842","volume":"40","author":"N Solari","year":"2013","unstructured":"Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40:192\u2013200.","journal-title":"J Rheumatol"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2012.11.008","volume":"147","author":"C Kessel","year":"2013","unstructured":"Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147:229\u201341.","journal-title":"Clin Immunol"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/art.30290","volume":"63","author":"LC Grevers","year":"2011","unstructured":"Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, et al. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis. Arthritis Rheum. 2011;63:1365\u201375.","journal-title":"Arthritis Rheum"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X","volume":"43","author":"M Frosch","year":"2000","unstructured":"Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628\u201337.","journal-title":"Arthritis Rheum"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266\u201373.","journal-title":"JAMA"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","volume":"71","author":"J Gerss","year":"2012","unstructured":"Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71:1991\u20137.","journal-title":"Ann Rheum Dis"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","volume":"71","author":"D Holzinger","year":"2012","unstructured":"Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974\u201380.","journal-title":"Ann Rheum Dis"},{"key":"723_CR12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","volume":"52","author":"H Moncrieffe","year":"2013","unstructured":"Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology (Oxford). 2013;52:1467\u201376.","journal-title":"Rheumatology (Oxford)"},{"key":"723_CR13","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202\u20139.","journal-title":"Arthritis Rheum"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Childhood Arthritis Rheumatology Research A, Pediatric Rheumatology Collaborative Study G, Paediatric Rheumatology International Trials O. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929\u201336.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366.","journal-title":"Arthritis Rheum"},{"key":"723_CR17","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol"},{"key":"723_CR18","first-page":"1058","volume":"29","author":"HI Brunner","year":"2002","unstructured":"Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002;29:1058\u201364.","journal-title":"J Rheumatol"},{"key":"723_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383\u201391.","journal-title":"Lancet"},{"key":"723_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135.","journal-title":"Cancer"},{"key":"723_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.24087","volume":"61","author":"HM Albers","year":"2009","unstructured":"Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:46\u201351.","journal-title":"Arthritis Rheum"},{"key":"723_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","volume":"74","author":"IY Choi","year":"2015","unstructured":"Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499\u2013505.","journal-title":"Ann Rheum Dis"},{"key":"723_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/rheumatology\/ket375","volume":"53","author":"MT Rahman","year":"2014","unstructured":"Rahman MT, Myles A, Gaur P, Misra R, Aggarwal A. TLR4 endogenous ligand MRP8\/14 level in enthesitis-related arthritis and its association with disease activity and TLR4 expression. Rheumatology (Oxford). 2014;53:270\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"723_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acr.22248","volume":"66","author":"F Rothmund","year":"2014","unstructured":"Rothmund F, Gerss J, Ruperto N, Dabritz J, Wittkowski H, Frosch M, et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66:949\u201355.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","volume":"71","author":"M Bulatovic","year":"2012","unstructured":"Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:1484\u20139.","journal-title":"Ann Rheum Dis"},{"key":"723_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/s10165-009-0187-8","volume":"19","author":"N Iwamoto","year":"2009","unstructured":"Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488\u201392.","journal-title":"Mod Rheumatol"},{"key":"723_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jbspin.2010.02.026","volume":"77","author":"H Marotte","year":"2010","unstructured":"Marotte H, Miossec P. Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint, Bone, Spine. 2010;77:297\u2013305.","journal-title":"Joint, Bone, Spine"},{"key":"723_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10067-012-2146-6","volume":"32","author":"C Pomirleanu","year":"2013","unstructured":"Pomirleanu C, Ancuta C, Miu S, Chirieac R. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol. 2013;32:665\u201370.","journal-title":"Clin Rheumatol"},{"key":"723_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2011.599073","volume":"41","author":"MK Soderlin","year":"2012","unstructured":"Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1\u20139.","journal-title":"Scand J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0723-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0723-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:08:48Z","timestamp":1728907728000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0723-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0723-1","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,7]]},"assertion":[{"value":"17 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"200"}}